IBA sells its first Rhodotron Lite in China, an alternative to cobalt-60
The X-ray irradiation system, sold shortly after its commercial launch, will be installed at an irradiation services center in the Guangdong province, in southern China.
In its press release of November 20, 2026, the Belgian group presents this first order as confirmation of its strategic direction, against a backdrop of supply difficulties for cobalt-60.
A small-scale X-ray offering facing gamma installations
According to IBA, the Rhodotron Lite offers processing capacities equivalent to those of a gamma irradiation system with an activity exceeding one million curies of cobalt-60. The group highlights a moderate annual throughput and broad adaptability to products.
IBA thus positions it as an alternative to a wide range of gamma systems using 1 to 2 million curies of cobalt-60 worldwide.
The group justifies this direction by market conditions: according to it, cobalt-60 is becoming less and less accessible and its prices remain high on a global scale. IBA believes that the Rhodotron Lite overall outperforms gamma systems in terms of cost-effectiveness and sustainability, while avoiding the environmental burden associated with this radioactive source.
Guangdong as the first site, with export to developing countries in sight
Once installed, the system is to provide comprehensive irradiation technologies for the southern China region and meet the varied needs of Guangdong customers. The group states that by deploying X-ray technology, it intends to strengthen its position in irradiation services in China.
“This rapid first sale confirms our strategic direction,” said Thomas Servais, President of IBA Industrial. He describes a solution that gives customers “initial access to sustainable X-ray technology” and helps offset cobalt supply difficulties.
The executive also places the system within the “Healthy China” strategy and within a logic of technological diversification. According to him, the Rhodotron Lite “facilitates access to X-ray technology in China and other countries, particularly in developing countries”.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Context
Period
Period: S1 2026
Key reported figures
Revenue: 323,7 millions d'euros
Quarterly revenue: 323,7 millions d'euros
EBITDA: 21,8 millions d'euros
EBITDA margin: 8,2 %
Net income: 9,3 millions d'euros
81 millions d'euros
Guidance from the release
Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées, reflétant la confiance du Groupe dans ses perspectives pour l'ensemble de l'année.
Risks mentioned
Surcapacité persistante sur le marché d'Industrial Solutions malgré un pipeline actif.
Retards temporaires de facturation liés à la migration ERP qui ont impacté la position financière nette.
Dosimetry reste sous pression malgré les mesures de réduction des coûts.
Opportunities identified
Forte dynamique commerciale en Proton Therapy avec cinq salles vendues et cinq prises de commandes de plus de €148 millions au S1.
PanTera a obtenu la qualification de fournisseur c-GMP d'actinium-225 et extension de collaboration avec TerraPower Isotopes pour tripler la capacité de production en Belgique.
Amélioration continue de la rentabilité : marge brute passée de 29,5% à 33,7% et EBITDA ajusté en croissance de 63%.
Outlook / guidance
Management commentary: Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées à au moins € 32 millions
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.